Compare SGBX & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGBX | TXMD |
|---|---|---|
| Founded | 2007 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.0M | 21.3M |
| IPO Year | 2017 | N/A |
| Metric | SGBX | TXMD |
|---|---|---|
| Price | $2.41 | $1.68 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 13.7M | 93.0K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | ★ $3,382,896.00 | $2,796,000.00 |
| Revenue This Year | $1,628.82 | $427.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $264.45 |
| Revenue Growth | N/A | ★ 75.19 |
| 52 Week Low | $1.81 | $0.70 |
| 52 Week High | $122.88 | $2.44 |
| Indicator | SGBX | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 41.57 | 52.34 |
| Support Level | $3.30 | $1.62 |
| Resistance Level | $4.05 | $2.01 |
| Average True Range (ATR) | 0.51 | 0.17 |
| MACD | -0.14 | -0.02 |
| Stochastic Oscillator | 2.36 | 41.38 |
Safe & Green Holdings Corp is a modular solutions company. The company currently provides modules made out of both code-engineered cargo shipping containers and wood for use as both permanent or temporary structures for residential housing use and commercial use, including for health care facilities. It operates in four segments: construction services; medical; real estate development; and environmental. The company generates the majority of its revenue from the Construction segment includes the company's manufacturing unit SG ECHO and other modules projects.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.